Abstract
Cytomegalovirus (CMV) retinitis is the leading cause of blindness in patients with acquired immune deficiency syndrome (AIDS). Before improved therapeutic approaches can be developed to manage this devastating sight- threatening disease, specific questions pertinent to the pathophysiology of CMV retinitis must be addressed. These questions relate to the origin of virus responsible for retinitis, spread of virus within the retina, the immunopathogenesis of retinal destruction, and the fate of virus during traditional antiviral therapy. In this review, we examine for each question the clinical rationale, the experimental data, and the clinical implications associated with these data. In particular, two experimental systems are emphasized. One is an in vitro system to study the susceptibility of human retinal pigment epithelium to CMV infection. The other involves clinically- relevant murine models of CMV retinitis, especially one of retrovirus- induced immunodeficiency (MAIDS). We suggest that immune-based therapy alone or in combination with traditional chemotherapy offers improved prospects for maintaining subclinical CMV infection in the immunosuppressed individual, thereby preventing CMV retinitis.
| Original language | English |
|---|---|
| Pages (from-to) | 112-118 |
| Number of pages | 7 |
| Journal | Regional immunology |
| Volume | 6 |
| Issue number | 1-2 |
| State | Published - Dec 1 1994 |
Fingerprint
ASJC Scopus subject areas
- Immunology
Cite this
Cytomegalovirus retinitis during AIDS : Current issues and future directions. / Dix, R. D.; Cray, Carolyn; Cousins, S.
In: Regional immunology, Vol. 6, No. 1-2, 01.12.1994, p. 112-118.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cytomegalovirus retinitis during AIDS
T2 - Current issues and future directions
AU - Dix, R. D.
AU - Cray, Carolyn
AU - Cousins, S.
PY - 1994/12/1
Y1 - 1994/12/1
N2 - Cytomegalovirus (CMV) retinitis is the leading cause of blindness in patients with acquired immune deficiency syndrome (AIDS). Before improved therapeutic approaches can be developed to manage this devastating sight- threatening disease, specific questions pertinent to the pathophysiology of CMV retinitis must be addressed. These questions relate to the origin of virus responsible for retinitis, spread of virus within the retina, the immunopathogenesis of retinal destruction, and the fate of virus during traditional antiviral therapy. In this review, we examine for each question the clinical rationale, the experimental data, and the clinical implications associated with these data. In particular, two experimental systems are emphasized. One is an in vitro system to study the susceptibility of human retinal pigment epithelium to CMV infection. The other involves clinically- relevant murine models of CMV retinitis, especially one of retrovirus- induced immunodeficiency (MAIDS). We suggest that immune-based therapy alone or in combination with traditional chemotherapy offers improved prospects for maintaining subclinical CMV infection in the immunosuppressed individual, thereby preventing CMV retinitis.
AB - Cytomegalovirus (CMV) retinitis is the leading cause of blindness in patients with acquired immune deficiency syndrome (AIDS). Before improved therapeutic approaches can be developed to manage this devastating sight- threatening disease, specific questions pertinent to the pathophysiology of CMV retinitis must be addressed. These questions relate to the origin of virus responsible for retinitis, spread of virus within the retina, the immunopathogenesis of retinal destruction, and the fate of virus during traditional antiviral therapy. In this review, we examine for each question the clinical rationale, the experimental data, and the clinical implications associated with these data. In particular, two experimental systems are emphasized. One is an in vitro system to study the susceptibility of human retinal pigment epithelium to CMV infection. The other involves clinically- relevant murine models of CMV retinitis, especially one of retrovirus- induced immunodeficiency (MAIDS). We suggest that immune-based therapy alone or in combination with traditional chemotherapy offers improved prospects for maintaining subclinical CMV infection in the immunosuppressed individual, thereby preventing CMV retinitis.
UR - http://www.scopus.com/inward/record.url?scp=0028652372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028652372&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0028652372
VL - 6
SP - 112
EP - 118
JO - Regional immunology
JF - Regional immunology
SN - 0896-0623
IS - 1-2
ER -